Pfizer Stock - Weekly review and sector comparison after oncology deal updates

Pfizer stock closes a week marked by fresh oncology deal headlines and continued post-pandemic repositioning. A look at how the US pharma group measures up against big pharma peers and what the latest pipeline and revenue mix shifts mean for investors.

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 19:05 UTC. Details in the imprint.

Pfizer (US7170811035) is closing out the week with investors still digesting its post-pandemic realignment and recent oncology deal headlines. Against this backdrop, the US pharma group remains under scrutiny as markets compare its growth profile with other large drug makers.

What the latest filings show

Pfizer’s most recent quarterly report for the first quarter of 2025 showed revenue of $14.9 billion, with continued normalization of COVID-19 product sales and growth in non-COVID franchises such as Eliquis and Vyndaqel/Vyndamax. The company’s Q1 2025 Form 10-Q details the shifting revenue mix.

The company reiterated its 2025 revenue guidance range of $58 billion to $61 billion in its April 2025 earnings materials, emphasizing contributions from recently acquired brands and pipeline launches outside vaccines. Management again underscored its goal of returning to a more balanced portfolio after the pandemic spike in Comirnaty and Paxlovid sales.

Weekly review and peer comparison

This week, large pharma stocks in the US traded in relatively narrow ranges as investors weighed macro data and sector-specific updates. Pfizer shares have continued to reflect a transition story, with COVID windfalls fading and newer products and acquisitions expected to carry growth over the medium term.

Compared with peers such as Johnson & Johnson, Merck and Bristol Myers Squibb, Pfizer currently trades at a valuation that reflects both its still-elevated cash generation and uncertainty around the speed of ramp-up in its oncology and rare disease pipelines. Sector ETFs tracking big pharma have generally held up better than the broader market during risk-off phases, underscoring the defensive tilt of the group.

How the company makes money

Pfizer generates revenue primarily from patented prescription medicines and vaccines across oncology, cardiovascular, rare diseases, immunology and infectious diseases. Key products include the anticoagulant Eliquis, heart-failure therapy Vyndaqel/Vyndamax, pneumococcal vaccines, and a growing portfolio of oncology drugs, supplemented by milestone and collaboration payments.

Where the stock trades today

Pfizer shares (US7170811035) trade on the New York Stock Exchange at $28.50 as of 06/20/2026, 19:00 UTC.

Key facts on Pfizer stock

• Company: Pfizer Inc.
• ISIN: US7170811035
• WKN: 852009
• Ticker: PFE
• Venue: NYSE
• Price (as of 06/20/2026, 19:00 UTC): 28.50 USD
• Market cap: 160,000,000,000 USD (as of 06/20/2026)
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: Standard & Poor's 500 index, Dow Jones Industrial Average
• Next earnings date: 08/01/2026

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.